Moderna Inc. (MRNA)
NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MRNA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $78.44B
- EPS (TTM)
- -$7.98
- Dividend yield
- None
- 52-week range
- 22.28 – 212.22
- Day range
- 182.51 – 197.65
- Volume / Avg
- 14.60M / 17.31M
- Beta
- —
- Shares outstanding
- 399.24M
- Next earnings
- Nov 5, 2026
52-week range
MRNA stock today
Shares of Moderna (MRNA) finished higher on Oct 7 at $196.48, a gain of 4.81% or $9.02 per share, versus the S&P 500's 0.22% decline. At this level, MRNA sits near the top of its 52-week range of $22.28 to $212.22: 7.4% below the high, set on Oct 6, 2026 and 781.9% above the low. MRNA is up 560.1% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 612.0%.
Moderna has posted a net loss over the last twelve months (EPS of -$7.98), so its P/E ratio is not meaningful. Moderna's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Moderna
Company profileModerna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Stéphane Bancel M.B.A.
- Headquarters
- Cambridge, MA
- Employees
- 4,700
- IPO year
- 2018
- Website
- modernatx.com
Financial highlights
Full financialsIn fiscal 2025, Moderna generated $1.94 billion in revenue, down 39.9% from fiscal 2024, its first annual decline since 2024. Moderna reported a net loss of $2.82 billion, compared with a loss of $3.56 billion a year earlier. Gross margin was 55.3% (up from 54.8%) and operating margin -158.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.94B | $3.24B | $6.85B | $19.26B | $18.47B |
| Growth | -39.93% | -52.75% | -64.45% | +4.29% | +2200.25% |
| Net income | $-2.82B | $-3.56B | $-4.71B | $8.36B | $12.20B |
| EPS (diluted) | $-7.26 | $-9.28 | $-12.33 | $20.12 | $28.29 |
Analyst forecast
ForecastConsensus (23 analysts)
hold
Avg. price target
$121.00-38.42%
- Strong buy 1
- Buy 4
- Hold 15
- Sell 2
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-1.08
- Last reported (Q2 2026)
- Jul 31, 2026
- EPS actual vs est.
- $-1.97 vs —
MRNA news
All MRNA news- Is Now the Time to Cash Out of the S&P 500's Top 3 Stocks of 2026?NasdaqSNDK, MRNA, DELL
- State attorneys general sue RFK Jr., seeking to reinstate childhood vaccine scheduleSeeking Alpha
- Biotech Stocks Tumble, With Recent Winners Moderna, Vaxcyte Among The Biggest LosersInvestor's Business DailyPCVX, MRNA
- Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity?NasdaqMRK, AZN, MRNA
- Moderna, Illumina lead healthcare gains in September as medtech dragsSeeking AlphaA, ILMN, MRNA
- Moderna, Illumina lead healthcare gains in September as medtech dragsSeeking AlphaTMO, ILMN, MRNA
- Moderna, Illumina lead healthcare gains in September as medtech dragsSeeking AlphaILMN, MRNA
- Notable analyst calls this week: Target, Moderna and PepsiCo among top picksSeeking AlphaOXY, PEP, MRNA
Moderna peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ARGXargenx SE ADR | 928.44 | -0.22% | $57.74B | vs MRNA |
| RVMDRevolution Medicines Inc. | 200.87 | +0.50% | $43.05B | vs MRNA |
| BIIBBiogen Inc. | 222.15 | -0.33% | $32.82B | vs MRNA |
| BNTXBioNTech SE ADR | 95.25 | -0.50% | $23.93B | vs MRNA |
| NBIXNeurocrine Biosciences Inc. | 143.47 | -1.40% | $14.58B | vs MRNA |
| EXELExelixis Inc. | 58.44 | +0.19% | $14.48B | vs MRNA |
| HALOHalozyme Therapeutics Inc. | 110.79 | +0.98% | $12.57B | vs MRNA |
| TECHBio-Techne Corp | 72.53 | +0.14% | $11.37B | vs MRNA |
Indexes, lists and sector
Index membership
Moderna stock FAQ
What is Moderna's stock price today?
MRNA last traded at $196.48 as of Oct 7, 4:00 PM EDT, up 4.81% on the day. Prices are delayed at least 15 minutes.
When is Moderna's next earnings date?
Moderna is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-1.08.
Is Moderna in the S&P 500?
Yes. Moderna (MRNA) is a constituent of the S&P 500 index.
Who is Moderna's CEO?
Mr. Stéphane Bancel M.B.A. is the chief executive officer of Moderna Inc., which has about 4,700 employees.
What is the MRNA 52-week high?
The 52-week high for MRNA is $212.22 and the 52-week low is $22.28. The stock is currently 7.4% below its high.